143 related articles for article (PubMed ID: 21782059)
1. Minimal residual disease detection in mantle cell lymphoma: technical aspects and clinical relevance.
Pott C
Semin Hematol; 2011 Jul; 48(3):172-84. PubMed ID: 21782059
[TBL] [Abstract][Full Text] [Related]
2. Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms.
Ferrero S; Drandi D; Mantoan B; Ghione P; Omedè P; Ladetto M
Hematol Oncol; 2011 Dec; 29(4):167-76. PubMed ID: 22678691
[TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.
Böttcher S; Ritgen M; Buske S; Gesk S; Klapper W; Hoster E; Hiddemann W; Unterhalt M; Dreyling M; Siebert R; Kneba M; Pott C;
Haematologica; 2008 Apr; 93(4):551-9. PubMed ID: 18379010
[TBL] [Abstract][Full Text] [Related]
4. Flow cytometric MRD detection in selected mature B-cell malignancies.
Böttcher S; Ritgen M; Kneba M
Methods Mol Biol; 2013; 971():149-74. PubMed ID: 23296963
[TBL] [Abstract][Full Text] [Related]
5. Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease.
Pott C; Schrader C; Brüggemann M; Ritgen M; Harder L; Raff T; Tiemann M; Dreger P; Kneba M
Eur J Haematol; 2005 Apr; 74(4):353-8. PubMed ID: 15777349
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C
Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970
[TBL] [Abstract][Full Text] [Related]
7. Four-color flow cytometry bypasses limitations of IG/TCR polymerase chain reaction for minimal residual disease detection in certain subsets of children with acute lymphoblastic leukemia.
Robillard N; Cavé H; Méchinaud F; Guidal C; Garnache-Ottou F; Rohrlich PS; Avet-Loiseau H; Garand R
Haematologica; 2005 Nov; 90(11):1516-23. PubMed ID: 16266899
[TBL] [Abstract][Full Text] [Related]
8. Detection of minimal residual disease in mantle cell lymphoma-establishment of novel eight-color flow cytometry approach.
Chovancová J; Bernard T; Stehlíková O; Šálek D; Janíková A; Mayer J; Doubek M
Cytometry B Clin Cytom; 2015 Mar; 88(2):92-100. PubMed ID: 25586981
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
Stark B; Avigad S; Luria D; Manor S; Reshef-Ronen T; Avrahami G; Yaniv I
Pediatr Blood Cancer; 2009 Jan; 52(1):20-5. PubMed ID: 19006253
[TBL] [Abstract][Full Text] [Related]
10. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
[TBL] [Abstract][Full Text] [Related]
11. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR.
Kerst G; Kreyenberg H; Roth C; Well C; Dietz K; Coustan-Smith E; Campana D; Koscielniak E; Niemeyer C; Schlegel PG; Müller I; Niethammer D; Bader P
Br J Haematol; 2005 Mar; 128(6):774-82. PubMed ID: 15755280
[TBL] [Abstract][Full Text] [Related]
12. The role of SOX11 in mantle cell lymphoma.
Lu TX; Li JY; Xu W
Leuk Res; 2013 Nov; 37(11):1412-9. PubMed ID: 24001358
[TBL] [Abstract][Full Text] [Related]
13. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.
Pott C; Hoster E; Delfau-Larue MH; Beldjord K; Böttcher S; Asnafi V; Plonquet A; Siebert R; Callet-Bauchu E; Andersen N; van Dongen JJ; Klapper W; Berger F; Ribrag V; van Hoof AL; Trneny M; Walewski J; Dreger P; Unterhalt M; Hiddemann W; Kneba M; Kluin-Nelemans HC; Hermine O; Macintyre E; Dreyling M
Blood; 2010 Apr; 115(16):3215-23. PubMed ID: 20032498
[TBL] [Abstract][Full Text] [Related]
14. [Tandem application of flow cytometry and polymerase chain reaction for choice targets of minimal residual disease in childhood acute lymphoblastic leukemia].
Tie LJ; Gu LJ; Jiang LM; Zhao JC; Chen J; Pan C; Dong L; Chen J; Xue HL; Tang JY; Wang YP
Zhongguo Dang Dai Er Ke Za Zhi; 2009 Apr; 11(4):246-50. PubMed ID: 19374803
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of flow cytometric immunophenotypic analysis for minimal residual disease detection in autologous stem-cell products of follicular and mantle cell lymphomas.
Kato H; Yamamoto K; Oki Y; Ine S; Taji H; Chihara D; Kagami Y; Seto M; Morishima Y
Leukemia; 2012 Jan; 26(1):166-9. PubMed ID: 21818114
[No Abstract] [Full Text] [Related]
16. Detection of minimal residual disease in acute leukemia.
van der Velden VH; Boeckx N; van Wering ER; van Dongen JJ
J Biol Regul Homeost Agents; 2004; 18(2):146-54. PubMed ID: 15471219
[TBL] [Abstract][Full Text] [Related]
17. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.
Brüggemann M; Schrauder A; Raff T; Pfeifer H; Dworzak M; Ottmann OG; Asnafi V; Baruchel A; Bassan R; Benoit Y; Biondi A; Cavé H; Dombret H; Fielding AK; Foà R; Gökbuget N; Goldstone AH; Goulden N; Henze G; Hoelzer D; Janka-Schaub GE; Macintyre EA; Pieters R; Rambaldi A; Ribera JM; Schmiegelow K; Spinelli O; Stary J; von Stackelberg A; Kneba M; Schrappe M; van Dongen JJ; ;
Leukemia; 2010 Mar; 24(3):521-35. PubMed ID: 20033054
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease as a surrogate marker for risk assignment to ALL patients.
Cazzaniga G; Gaipa G; Rossi V; Biondi A
Rev Clin Exp Hematol; 2003 Sep; 7(3):292-323. PubMed ID: 15024971
[TBL] [Abstract][Full Text] [Related]
19. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
[TBL] [Abstract][Full Text] [Related]
20. Detection of minimal residual disease in acute leukemia patients.
van Dongen JJ; Szczepański T; de Bruijn MA; van den Beemd MW; de Bruin-Versteeg S; Wijkhuijs JM; Tibbe GJ; van Gastel-Mol EJ; Groeneveld K; Hooijkaas H
Cytokines Mol Ther; 1996 Jun; 2(2):121-33. PubMed ID: 9384697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
